Join
Live feed
·
INSIDERFilingvia Quantisnow
Jounce Therapeutics Inc. logo

SEC Form 4: Duncan John Higgons sold $2,560 worth of Common Stock (200 units at $12.80), decreasing direct ownership by 2% to 9,913 units

ByQuantisnow·Wall Street's wire, on your screen.
JNCE· Jounce Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JNCE (Jounce Therapeutics Inc.) and more on Quantisnow.